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Objectives. The present study examined the association of
estrogen (E2) and the inflammatory response of endothelium in
coronary artery disease (CAD) by measuring circulating cellular
adhesion molecules (cCAMs) in subjects with atherosclerosis.
Background. Atherosclerotic plaque demonstrates features
similar to inflammation. Endothelial cell activation by inflamma-
tory cytokines induces expression of cellular adhesion molecules
(CAMs), thereby perhaps augmenting leukocyte adhesion and
recruitment and subsequent development of atherosclerosis. The
incidence of CAD is lower in women; this may be due to the
cardioprotective effects of E2.
Methods. Consecutive eligible subjects with CAD admitted for
cardiac catheterization were studied. The groups evaluated were
men, postmenopausal women receiving E2 replacement therapy
(ERT), postmenopausal women not receiving ERT and premeno-
pausal women. Control groups included men and women without
CAD. Preprocedural blood samples were drawn from all groups.
Measurements of cCAMs, E-selectin, vascular cell adhesion
molecule-1 (VCAM-1) and intercellular adhesion molecule-1 were
performed by enzyme-linked immunoabsorbant assay. E2 levels
were assessed by radioimmunoassay.
Results. We observed a statistically significant increase in all
cCAMs in men with CAD and postmenopausal women with CAD
not receiving ERT compared with postmenopausal women with
CAD receiving ERT. Premenopausal women with CAD and post-
menopausal women with CAD receiving ERT had a significant
increase in VCAM-1 alone compared with the female control
group.
Conclusions. A possible mechanism by which E2 exerts one of
its cardioprotective effects is by limiting the inflammatory re-
sponse to injury by modulating the expression of CAMs from the
endothelium.
(J Am Coll Cardiol 1998;31:1555–60)
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Pathologic examination has demonstrated similarities between
inflammation and atherosclerosis (1). The endothelial cell
contributes actively to the development of local vascular
immune and inflammatory responses. Intercellular adhesion
between vascular endothelial cells and circulating leukocytes
initiates many of these responses (2). The modulation of
leukocyte–endothelial adhesion is thought to be mediated by
cellular adhesion molecules (CAMs), which include E-selectin,
vascular cell adhesion molecule-1 (VCAM-1) and intercellular
adhesion molecule-1 (ICAM-1) and -2. These molecules are
associated with enhanced leukocyte adhesion, as well as en-
hanced surface thrombogenicity and intravascular coagulation,
observed in early atherosclerosis (3). Recently soluble isoforms
of CAMs have been measured in the circulation and correlated
with disease activity. Increased levels of soluble E-selectin have
been demonstrated in patients with polyarteritis nodosum,
scleroderma, giant cell arteritis, sepsis and diabetes mellitus
(4). This suggests endothelial activation in these patients
because the expression of E-selectin is only found on activated
endothelium. The soluble ICAM-1 and VCAM-1 levels have
been reported to be elevated in patients with cancer, inflam-
matory disease and infection (5–8). In addition, a recent report
demonstrated abnormal levels of CAMs in the circulation in
atherosclerosis (9).
The incidence of coronary atherosclerosis in premeno-
pausal women is half that observed in age-matched men (10).
After menopause the incidence of cardiovascular disease in-
creases, but estrogen (E2) replacement therapy (ERT) signif-
icantly reduces this risk. The protective effect of E2 is not
completely understood. E2 affects cholesterol metabolism;
however, the magnitude of the lipid changes cannot fully
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account for the observed cardiovascular protective effects
(11,12).
E2 is a steroid hormone whose response is mediated by
specific intracellular receptors (13). The hormone initiates
diverse physiologic responses by binding to its receptor in the
target cell, and E2 receptors have been demonstrated in
endothelial cells (14). Modulation of transcription of CAMs in
vitro by E2 through its receptor has functional implications for
leukocyte adhesion to endothelial cells (14). This relation in
turn could influence development of atherosclerosis.
The purpose of the present study was to evaluate the
association of ERT and the inflammatory response of the
endothelium in coronary artery disease (CAD) by examining
circulating cellular adhesion molecules (cCAMs) in subjects
with atherosclerosis. This investigation into the relation be-
tween inflammation and atherosclerosis in the presence of
ERT may provide insight into the cardioprotective effect of the
hormone.
Methods
Subjects. Consecutive subjects with clinical evidence of
CAD admitted for cardiac catheterization between July 1996
and September 1997 were screened for entry into the present
study. CAD was defined as lumen irregularities or stenoses
.50% in at least one vessel. The subjects were divided into
four groups: 1) men, 2) postmenopausal women receiving oral
ERT in the form of a conjugated equine E2, 3) postmeno-
pausal women not receiving ERT, and 4) premenopausal
women. Control groups included volunteer medical center
employees, men and premenopausal women, all with no clin-
ical evidence of CAD by history. One hundred seventy-five
subjects were evaluated for the present study. Exclusion crite-
ria included acute myocardial infarction, hemodynamic insta-
bility, the use of progesterone, ERT by topical application,
recent viral illness, active inflammatory or connective tissue
disease and clinically significant systemic illness. Menopause
was defined as .6 months since last menses. At least 6 months
of therapy was required for inclusion in the study group
receiving ERT. Physical examination, blood pressure, electro-
cardiography, complete blood count, clinical chemistry and
liver and renal function tests were performed before entry in
the present study. The control groups were evaluated for
clinically significant CAD by history and physical examination.
The study protocol was approved by the Human Investigation
Committee, Yale University School of Medicine. Written
informed consent was obtained from all subjects before inclu-
sion in the study.
Protocol. Subjects who fulfilled entry criteria and agreed to
participate in the present study were entered in a consecutive
manner over a 14-month (July 1996 to September 1997)
period. On entry into the study a data sheet for clinical and
cardiac risk profile was completed. Potential subjects had
preprocedural blood samples drawn on the morning of their
procedure and were entered into the study if significant CAD
was present at catheterization. Significant disease was defined
as at least one vessel with .50% angiographic stenosis.
Coronary angiograms were read in a double-blind manner.
Serum samples were stored at 220°C. Because of differences in
the absolute levels for circulating ICAM-1, VCAM-1 and
E-selectin (cICAM-1, cVCAM-1 and cE-selectin), cCAM data
were normalized to measured cCAM levels in premenopausal
control subjects and expressed as the percent increase over
control values when all three cCAMs were compared between
groups.
Laboratory assays. All serum samples were stored at
220°C and assayed in duplicate (E2 levels) or triplicate (cCAM
levels). Circulating E2 levels were measured using a commer-
cially available radioimmunoassay (Diagnostic Products Cor-
poration), according to the manufacturers’ instructions. The
intraassay and interassay coefficients of variation were 5.8%
and 6.0%, respectively, for E2. The E2 antiserum is specific for
17beta-estradiol, with low cross-reactivity to other steroids. A
standard curve was included with all assays, and concentrations
of E2 were determined and expressed as pmol/liter.
Enzyme-linked immunoabsorbant assay (ELISA) for circu-
lating cellular adhesion molecules was performed with com-
mercially available ELISA kits for cE-selectin, cICAM-1 and
cVCAM-1 (R & D Systems). There was no cross-reactivity with
other adhesion molecules. Dilution curves of the serum sam-
ples were parallel to standard dilution curves. The interassay
and intraassay coefficients of variation were ,8%, as deter-
mined in human serum. The normal ranges of cCAMs in our
study were obtained from 20 healthy male volunteers
(cICAM-1 245 6 58 ng/ml; cVCAM-1 640 6 165 ng/ml;
cE-selectin 44 6 29 ng/ml) and 20 women (cICAM-1 225 6 50
ng/ml; cVCAM-1 475 6 145 ng/ml; cE-selectin 35 6 19 ng/ml)
and are in accordance with those published (15); normal men
were noted to have increased levels of all cCAMs compared
with premenopausal female control subjects; however, the
increase was not statistically significant. This observation also
has been previously reported (16).
Statistical analysis. Results are expressed as mean value 6
SD. Differences among the groups were compared by a
one-way factorial analysis of variance and then by the Tukey
test for multiple comparisons. Correlations between serum E2
levels and cCAM levels were examined using simple linear
Abbreviations and Acronyms
CAD 5 coronary artery disease
CAM 5 cellular adhesion molecule
cCAM 5 circulating cellular adhesion molecule
cE-selectin 5 circulating E-selectin
cICAM-1 5 circulating intercellular adhesion molecule-1
cVCAM-1 5 circulating vascular cell adhesion molecule-1
E2 5 estrogen
ERT 5 estrogen replacement therapy
ICAM-1 5 intercellular adhesion molecule-1
VCAM-1 5 vascular cell adhesion molecule-1
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regression analysis by the least squares method. The differ-
ences were considered statistically significant at p , 0.05.
Results
Clinical characteristics. Table 1 summarizes the subject
and control groups and their mean E2 level 6 SD. There was
a significant difference (p , 0.05) in E2 levels in men and
postmenopausal women with CAD not receiving ERT com-
pared with the other groups. The E2 levels in both of these
groups are consistent with measurements reported for post-
menopausal women. Both groups of premenopausal women
had comparable E2 levels despite control women being
younger. The E2 level in postmenopausal women with CAD
receiving ERT was lower than that measured in the premeno-
pausal groups. All ERT had a daily dosing schedule, significant
fluctuations in levels were not observed.
The clinical characteristics are summarized in Table 2. The
age of postmenopausal women was not significantly different
between groups receiving or not receiving ERT. There were no
statistically significant differences in the cardiac risk factors of
hypertension, cigarette use, diabetes mellitus and total choles-
terol/low density lipoprotein. A small, but statistically signifi-
cant, increase in the use of lipid-lowering agents in men with
CAD compared with women with CAD was observed. There
was a statistically significant difference in high density lipopro-
tein and triglyceride levels in postmenopausal women with
CAD receiving ERT compared with men with CAD and
postmenopausal women with CAD not receiving ERT.
Linear regression analysis demonstrated a significant cor-
relation for a biologic system between E2 levels in women and
cCAMs: cE-selectin (y 5 20.043x 1 38.847, r2 5 0.333, p ,
0.05); cICAM-1 (y 5 20.418x 1 348.518, r2 5 0.339, p , 0.05);
cVCAM-1 (y 5 20.697x 1 784.418, r2 5 0.276, p , 0.05).
cCAM Levels. Figure 1 demonstrates the absolute levels
(ng/ml) of cE-selectin, cICAM-1, and cVCAM-1 in the groups
studied. The levels of cICAM-1 and cE-selectin are signifi-
cantly higher in men with CAD and postmenopausal women
with CAD not receiving ERT compared with the other groups.
The increase in all cCAMs is comparable in men with CAD
and postmenopausal women with CAD not receiving ERT.
The level of cVCAM-1 is significantly elevated in all groups
with CAD.
cCAM levels in postmenopausal women with CAD receiving
or not receiving ERT. The association of ERT and cCAMs in
postmenopausal women with CAD is shown in Figure 2. All
data for cCAM levels were normalized to cCAM levels in
control premenopausal women and expressed as the percent
increase in cCAMs over this baseline. There is a statistically
significant increase in cE-selectin, cICAM-1 and cVCAM-1 in
postmenopausal women with CAD not receiving ERT com-
pared with postmenopausal women with CAD receiving ERT.
Thus ERT is associated with a decrease in all cCAM levels in
postmenopausal women with CAD. The increase in cE-selectin
and cICAM-1 in postmenopausal women with CAD receiving
ERT is not statistically significant compared with the premeno-
pausal control group; however, the elevation in cVCAM-1 is
significant.
cCAM levels in men with CAD. There is a statistically
significant increase in the levels of all cCAMs (cE-selectin,
cICAM-1 and cVCAM-1) in men with CAD compared with
male control subjects (Fig. 3). The basal expression of cCAMs
in male control subjects is greater than that observed in female
Table 1. Study Groups and Estradiol Levels
No. of
Subjects
Estradiol (pmol/liter)
(mean 6 SD)
Premenopausal control 20 320 6 60
Premenopausal CAD(1) 10 300 6 69
Postmenopausal CAD(1), ERT(1) 25 150 6 65
Postmenopausal CAD(1), ERT(2) 50 30 6 24*
Male control 20 38 6 10*
Male CAD(1) 50 20 6 8*
*p , 0.05 versus premenopausal women and women receiving ERT. CAD 5
coronary artery disease; ERT 5 estrogen replacement therapy; (1) 5 with
disease or receiving therapy; (2) 5 without disease or not receiving therapy.
Table 2. Clinical Characteristics
Premenopausal
Control
(n 5 20)
Premenopausal
(1)CAD
(n 5 10)
Postmenopausal
(1)ERT,
(1)CAD
(n 5 25)
Postmenopausal
(2)ERT,
(1)CAD
(n 5 50)
Male
Control
(n 5 20)
Male
(1)CAD
(n 5 50)
Age (yr) 33 6 6 43 6 5 62 6 10 60 6 15 29 6 8 55 6 16
Anti-HTN medication 0% 20% 68% 50% 10% 63%
Smoke 5% 50% 48% 50% 10% 50%
DM 0% 20% 34% 30% 0% 20%
Cholesterol (mg/dl) 186 6 24 220 6 23 200 6 30 218 6 34 205 6 34 219 6 30
HDL (mg/dl) 49 6 3 36 6 4 39 6 4 30 6 3* 40 6 5 32 6 3.7*
LDL (mg/dl) 118 6 12 130 6 10 129 6 14 140 6 16 130 6 15 139 6 11
TGs (mg/dl) 148 6 58 228 6 68 180 6 66 250 6 63* 214 6 30 230 6 28*
Lipid medication 0 0 20% 20% 0 37%†
*p , 0.05 versus postmenopausal women with coronary artery disease (CAD) receiving estrogen replacement therapy (ERT). †p , 0.05 versus postmenopausal
women with CAD. Data presented are mean value 6 SD or percent of patients. DM 5 diabetes mellitus; HDL 5 high density lipoprotein; HTN 5 hypertension; LDL 5
low density lipoprotein; TG 5 triglycerides.
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control subjects; this is not statistically significant and has been
previously described (16).
Discussion
Studies of atherosclerotic lesions in human coronary arter-
ies and aortas demonstrate an increased expression of ICAM-1
and E-selectin on endothelial cells adjacent to sites of inflam-
matory cell infiltrates (3). The effects of E2 on the development
of atherosclerosis have demonstrated inhibition of myointimal
proliferation with injury (17), platelet aggregation (18), foam
cell formation (19) and increased arterial smooth muscle
prostacyclin production (20). E2 also influences the expression
of plasminogen activator inhibitor type 1 (21).
Statistical significance. We demonstrate that ERT in post-
menopausal women with CAD is associated with a statistically
significant decrease in the levels of cE-selectin, cICAM-1 and
cVCAM-1 compared with postmenopausal women with CAD
not receiving ERT and men with CAD. This suggests a possible
alteration in the expression of CAMs in atherosclerosis that
may be associated with ERT. These findings support in vitro
data, which demonstrated E2 treatment of human endothelial
cells inhibited cytokine-induced expression of CAMs (14). This
investigation suggests one of the protective roles of E2 may be
the regulation of CAM expression in atherosclerosis, which
may be detected by the circulating levels of these molecules.
Exclusion of postmenopausal women receiving combined
E2/progesterone therapy avoided possible effects of the pro-
gestational agent on the amount of E2 receptor present or
interactions with other steroids and receptors. Women receiv-
ing ERT by patch administration were not enrolled because of
differences in biologic effects from the route of administration
(22). Clinical characteristics and cardiac risk profiles were
generally similar among the study groups. There were differ-
ences in the overall age of the groups, the use of lipid-lowering
agents (increased in the men with CAD), and high density
lipoprotein/triglyceride levels in premenopausal women and
postmenopausal women receiving ERT.
Potential mechanisms. Few studies have investigated the
hormonal regulation of CAM expression. A previous report
showed that dexamethasone interacts with the glucocorticoid
receptor and results in reduction of interleukin-1–induced
E-selectin mRNA levels (23). Another study has reported
reduced VCAM-1 mRNA and membrane protein levels in
E2-pretreated, interleukin-1–activated cells (24). E2 markedly
inhibits interleukin-1–induced endothelial CAM transcription
in endothelial cells, also reflected in decreased membrane
protein expression and cytokine-induced leukocyte adhesion
(14). The importance of cCAMs in various inflammatory
diseases has been investigated (25,26). The association of
CAMs in their tissue form with atherosclerosis has been
described. Elevation of adhesion molecules in the tissue are
usually associated with increased circulating levels (25,26). The
present report demonstrates for the first time, that E2, which
suppresses induction of these adhesion molecules in vitro, is
associated with decreased levels of cCAMs in vivo. Speculation
Figure 1. cCAM levels (ng/ml) in all study groups. Top, cE-selectin.
Middle, cICAM-1. Bottom, cVCAM-1. All assays were performed in
triplicate. HRT 5 hormone replacement therapy (ERT); 1 5 with;
2 5 without. *p , 0.05 versus premenopausal control subjects.
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on a possible mechanism for the decreased levels of adhesion
molecules in the circulation with ERT, on the basis of our in
vivo and in vitro studies, would include 1) downregulation of
the gene transcription of the molecules, 2) subsequent de-
creased surface expression on the endothelium, and 3) finally,
a decreased level found in the circulation. E2 may exert part of
its cardioprotective effects by modulating the systemic expres-
sion of cCAMs. Blann et al. (26) demonstrated elevation of
these molecules in inflammatory vascular diseases, ischemic
heart disease and peripheral vascular disease.
Study limitations. Limitations of this study are that we
cannot rule out other possible mechanisms for the measured
differences in cCAM levels. The mechanisms by which adhe-
sion molecules are shed, released and cleared from the circu-
lation probably affect circulating levels. These mechanisms
remain unclear and are currently under investigation.
The oxidative modification of low density lipoprotein has
been suggested as initiating the development of atherosclerotic
lesions. In animal models antioxidants inhibit the development
of atherosclerosis (27). E2 may have antioxidant properties
(28). It is possible that the decreased levels of cCAMs mea-
sured in the present report are a result of an antioxidant effect
of ERT on low density lipoprotein. However, the major form
of E2 in conjugated equine E2, the ERT preparation used by
women enrolled in the present study, is estrone, which has
weak antioxidant properties compared with 17beta-estradiol
(29).
The effect of ERT on lipid metabolism as a possible
mechanism for our observations cannot be eliminated. De-
creased E2 production with menopause results in an increase in
low density lipoprotein cholesterol and lipoprotein(a) levels in
women. The use of oral ERT has been associated with an
increased high density lipoprotein and decreased low density
lipoprotein cholesterol levels. In both animal and human
studies E2 effects on high density lipoprotein and triglyceride
levels have been associated with a decrease in plaque forma-
tion and death from myocardial infarction (30). ERT may
result in a more favorable lipid profile, resulting in overall
plaque stability with decreased inflammation and subsequent
CAM induction and expression. Further prospective investiga-
tions into changes in plaque composition and lipid metabolism
as a result of ERT are ongoing and will be necessary to address
these issues.
The clinical relevance of cCAMs and the mechanisms
controlling the release of cCAMs is an area of active investi-
gation. However, our data suggest that E2 may be exerting its
cardioprotective effect, in part, by decreasing the inflammatory
response associated with atherosclerosis.
Figure 2. cCAM levels in postmenopausal women
with CAD receiving ERT [(1)HRT] versus those not
receiving ERT [(2)HRT]. The data presented were
normalized to cCAM levels in the premenopausal
control group and expressed as the percent increase in
cCAM. All assays were performed in triplicate.
HRT 5 hormone replacement therapy. *p , 0.05
versus postmenopausal women with CAD receiving
ERT. †p , 0.05 versus premenopausal control sub-
jects.
Figure 3. cCAM levels in men. The data presented were normalized to
cCAM levels in the premenopausal control group and expressed as the
percent increase in cCAM. All assays were performed in triplicate.
*p , 0.05 versus male control subjects.
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